Stacking GLP-1 drops with supporting compounds Beyond the GLP-1 medication itself, many people use supporting compounds to enhance their results
It was estimated that 12 participants would be appropriate to detect a difference with 80% power at the = 0.05 level
Dose increases should only occur when you tolerate your current dose well with minimal or no side effects
Stephanie Weiss, M.D., Ph.D., assistant director for the Clinical Research, Medication Development Program at NIDA, shared data from the first published clinical trial of GLP-1 RAs in alcohol use disorder: in patients with obesity with a BMI over 30, exenatide reduced heavy drinking days by 23.6% and lowered total alcohol intake
HRT replaces declining oestrogen and progesterone, which can help with metabolism and reduce belly fat
These six complications occurred in 23.7% of patients taking tirzepatide and 27.4% of those taking dulaglutide, a 16% lower risk for tirzepatide, a statistically significant difference. Gastrointestinal side effects were more common with tirzepatide, while other adverse events were similar between the two medications